The University of Oxford is a world-leading centre of learning, teaching and research and the oldest university in the English-speaking world. It is ranked first in the Times Higher Education’s World University Rankings – an international league table assessing universities across all activities, analysing their teaching, research, citations, industry collaboration and international outlook.
Modern Oxford is at the forefront of the full range of academic disciplines, including medical sciences, science and engineering, humanities and social sciences. Knowledge transfer and the development of new technologies are among its key priorities. The University’s collegiate system lies at the heart of its success, giving students and academics the benefit of belonging both to a large, internationally renowned institution and to an intimate, interdisciplinary academic community.
Oxford University Innovation Ltd is the University of Oxford’s research commercialisation company. Our role is to help University staff and students bring the benefits of their research and expertise to create impact in wider society.
We support Oxford’s researchers, staff and students, offering commercial skills and a range of specialist resources in order to maximise research impact. Income is shared with those involved according to the University’s Regulations, and profits from commercialisation are returned to the University for the benefit of future generations.
OSI turns world-leading science into world-beating companies, we come on board before traditional funds would. We partner early and for the long-term, because we understand that it takes time to turn disruptive science into an enduring business.
Sensyne Health plc is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of ethically sourced, anonymised patient data in collaboration with NHS Trusts. Alongside this, we develop clinically validated software applications that create clinician and patient benefit while providing highly curated data.
Anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company’s access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with NHS principles, UK data protection law and applicable regulatory guidance. Sensyne Health is an early signatory to the Department of Health and Social Care’s ‘Initial Code of Conduct for data-driven health and care technology’.
Our business aims to have a double bottom line, providing an attractive return to our shareholders and making a positive social impact; improving health and generating wealth that we share with our NHS Trust partners and the University of Oxford.
Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L) and is based in the Schrödinger Building, located on Oxford Science Park.
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading academic institutions, pharmaceutical and biotechnology companies, patient advocacy groups and venture capitalists. Drug discovery solutions are provided in form of integrated drug discovery alliances, development partnerships, licensing of innovative drug candidates and fee-for-service work. The Company operates worldwide and has leading scientific experts, state-of-the-art technologies as well as key therapeutic expertise in the areas of neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, fibrosis, respiratory and infectious diseases. By leveraging this expertise, Evotec intends to develop best-in-class and first-in-class differentiated therapeutics on its systematic, unbiased and comprehensive infrastructure.
Evotec has long-term discovery alliances with partners including Bayer, CHDI, Sanofi, Genentech and UCB. In addition, the Company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships e.g. with Sanofi in the field of diabetes as well as cancer immunotherapy, with Pfizer in the field of tissue fibrosis and Celgene in the field of neurodegenerative diseases. Moreover, Evotec is seeking to broaden its relationship with top-tier academic centres to accelerate the development of next-generation therapeutic approaches to treat or cure diseases with high unmet medical needs.
Evotec is built on integrated drug discovery know-how of over 20 years and is a leading player in the drug discovery field. The Company’s headquarters are located in Hamburg, Germany. Additional major operating sites exist in Abingdon and Macclesfield, UK; Goettingen and Munich, Germany; Toulouse, France; Verona, Italy; as well as Branford and Princeton, USA. Evotec has more than 2,100 employees worldwide.